N
JAZZ icon

Nuveen’s Jazz Pharmaceuticals JAZZ Stock Holding History

Nuveen’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-28,100
Closed -$4K – 3230
2019
Q4 		$4K Buy
+28,100
New +$3.82M ﹤0.01% 3205

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Nuveen's JAZZ Position: Q1 2026 in Review

Nuveen reduced its Jazz Pharmaceuticals (JAZZ) stake by 9.4% in Q1 2026, selling an estimated $6.25M and leaving 346,148 shares worth $65.4M. The position accounts for 0.02% of the portfolio, ranked #535.

Nuveen first reported a position in JAZZ in Q2 2013 and has held it in 50 quarters since. The position peaked at $274M in Q2 2019. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Nuveen held 346,148 shares of Jazz Pharmaceuticals worth $65.4M as of Q1 2026.
  • Nuveen sold 35,789 Jazz Pharmaceuticals shares in Q1 2026, an estimated $6.25M.
  • Jazz Pharmaceuticals made up 0.02% of Nuveen's portfolio in Q1 2026, its #535 holding.
  • Nuveen first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 50 quarters since.
  • Nuveen's Jazz Pharmaceuticals position peaked at $274M in Q2 2019.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.